Fenofibrate More Effective for T2DM Women Than Men
(HealthDay News) — For patients with type 2 diabetes, fenofibrate is effective in women, improving their lipoprotein profile more than in men, according to a study published online August 18 in Diabetologia.
Michael C. d'Emden, PhD, from the Royal Brisbane Hospital in Australia, and colleagues examined sex-related differences in the impact of fenofibrate on major cardiovascular events in type 2 diabetes. Data were included from 3,657 women and 6,138 men with type 2 diabetes, not using statins, who were allocated to fenofibrate or placebo for a five-year period.
The researchers found that, in both sexes, baseline total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apolipoproteins A-I and B, and triacylglycerol levels improved with fenofibrate (all P<0.001). In women, fenofibrate induced greater reductions in total cholesterol, LDL-C, non-HDL-C, and apolipoprotein B (all P<0.001), irrespective of menopausal status and statin intake. Fenofibrate reduced total cardiovascular outcomes by 30 and 13%, respectively, in women and men (P=0.008 and 0.07, respectively), after adjustment for confounders, with no indication of a treatment-by-sex interaction (P>0.1). Among patients with high triacylglycerol levels and low HDL-C, there were cardiac outcome reductions of 30 and 24% in women and men, respectively, with fenofibrate, with no indication of treatment-by-sex interaction (P>0.1).
"Both sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection," the authors write.
Several authors disclosed financial ties to Abbott Pharmaceuticals, which partially funded the study.